Literature DB >> 18206596

A comparative study of bacteremic and non-bacteremic pneumococcal pneumonia.

Francisco Jover1, José-María Cuadrado, Lucio Andreu, Silvia Martínez, Ruth Cañizares, Victoria Ortiz de la Tabla, Coral Martin, Pablo Roig, Jaime Merino.   

Abstract

BACKGROUND: Few attempts have been made to compare bacteremic and non-bacteremic pneumococcal pneumonia, mainly because it is difficult to gain agreement on which cases represent non-bacteremic pneumococcal pneumonia. Recently, an immunochromatographic assay for the detection of Streptococcus pneumoniae urinary antigen has been successfully evaluated for the diagnosis of pneumococcal pneumonia. The aim of our study was to examine and compare clinical and radiological features, risk factors, and outcome associated with bacteremic and non-bacteremic groups.
METHODS: A retrospective study (1995-2003) analyzing the clinical records of patients diagnosed with pneumococcal pneumonia in our institution was performed. S. pneumoniae were identified by blood cultures (bacteremic group) and detection of urinary antigen (non-bacteremic group).
RESULTS: There were 82 patients (57 bacteremic and 25 non-bacteremic). In seven non-bacteremic cases, another etiology was detected, i.e., Legionella (n=1) and Chlamydia pneumoniae (n=6). Bacteremic patients were significantly younger (p=<0.001), more likely to have liver disease (p=0.028), current smokers (p=0.024), alcohol and intravenous drug abusers (p=0.014 and p<0.001, respectively), and infected with HIV (p<0.001). Non-bacteremic patients were more likely to have congestive heart failure (p=0.004), chronic obstructive pulmonary disease (p=0.033) and to be former smokers (p=0.004). Bacteremic cases needed more prolonged intravenous antibiotic treatment (6 days vs. 4.5 days; p=0.006) than non-bacteremic cases and their length of stay was also longer.
CONCLUSION: In our study, smoking was the leading risk factor for pneumococcal pneumonia. However, current smokers have an increased risk of bacteremic forms and former smokers and patients with COPD developed non-bacteremic forms more frequently. Bacteremic patients need more prolonged intravenous antibiotic treatment than non-bacteremic patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18206596     DOI: 10.1016/j.ejim.2007.03.015

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  21 in total

Review 1.  Bacteraemic pneumococcal pneumonia: current therapeutic options.

Authors:  Charles Feldman; Ronald Anderson
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

2.  Kinase activity profiling of gram-negative pneumonia.

Authors:  Arie J Hoogendijk; Sander H Diks; Maikel P Peppelenbosch; Tom Van Der Poll; Catharina W Wieland
Journal:  Mol Med       Date:  2011-03-15       Impact factor: 6.354

3.  Validation of an immunodiagnostic assay for detection of 13 Streptococcus pneumoniae serotype-specific polysaccharides in human urine.

Authors:  Michael W Pride; Susanne M Huijts; Kangjian Wu; Victor Souza; Sherry Passador; Chunyan Tinder; Esther Song; Arik Elfassy; Lisa McNeil; Ronald Menton; Roger French; Janice Callahan; Chris Webber; William C Gruber; Marc J M Bonten; Kathrin U Jansen
Journal:  Clin Vaccine Immunol       Date:  2012-06-06

4.  Can we predict which patients with community-acquired pneumonia are likely to have positive blood cultures?

Authors:  Samuel George Campbell; R Andrew McIvor; Vincent Joanis; David Graydon Urquhart
Journal:  World J Emerg Med       Date:  2011

5.  Bacteraemic and non-bacteraemic/urinary antigen-positive pneumococcal community-acquired pneumonia compared.

Authors:  S P van Mens; A M M van Deursen; S C de Greeff; H E de Melker; L M Schouls; A van der Ende; M J M Bonten; E A M Sanders; B J M Vlaminckx
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-08-01       Impact factor: 3.267

6.  Guidelines for diagnosis and management of community- and hospital-acquired pneumonia in adults: Joint ICS/NCCP(I) recommendations.

Authors:  Dheeraj Gupta; Ritesh Agarwal; Ashutosh Nath Aggarwal; Navneet Singh; Narayan Mishra; G C Khilnani; J K Samaria; S N Gaur; S K Jindal
Journal:  Lung India       Date:  2012-07

7.  Impact of routine PCV7 (Prevenar) vaccination of infants on the clinical and economic burden of pneumococcal disease in Malaysia.

Authors:  Syed Aljunid; Gulifeiya Abuduxike; Zafar Ahmed; Saperi Sulong; Amrizal Muhd Nur; Adrian Goh
Journal:  BMC Infect Dis       Date:  2011-09-21       Impact factor: 3.090

8.  Prognostic factors for important clinical outcomes in patients with a severe infection.

Authors:  Charlotte F J van Tuijn; Maria Prins; Jan S Luitse; Suzanne E Geerlings
Journal:  Int J Emerg Med       Date:  2010-08-21

Review 9.  Potential role for mucosally active vaccines against pneumococcal pneumonia.

Authors:  Kondwani C Jambo; Enoch Sepako; Robert S Heyderman; Stephen B Gordon
Journal:  Trends Microbiol       Date:  2009-12-22       Impact factor: 17.079

10.  Impact of positive chest X-ray findings and blood cultures on adverse outcomes following hospitalized pneumococcal lower respiratory tract infection: a population-based cohort study.

Authors:  Marlene Skovgaard; Henrik C Schønheyder; Thomas Benfield; Rikke B Nielsen; Jenny D Knudsen; Jette Bangsborg; Christian Østergaard; Hans-Christian Slotved; Helle Bossen Konradsen; Lotte Lambertsen; Reimar W Thomsen
Journal:  BMC Infect Dis       Date:  2013-05-02       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.